US CRO Stock Surges 5% Despite Accounting Investigation Risks

ICON PLC (ticker: ICLR) closed 5.10% higher at $118.83 on the Nasdaq on April 15, adding roughly $500 million (about 660 billion Korean won) to its market capitalization, bringing it to around $90 billion (12.2 trillion won).

The stock had plunged 30–50% in a single day on February 12 after announcing an internal investigation into the appropriateness of its revenue recognition for 2023–2025 and a forthcoming financial restatement. Multiple law firms have since filed securities-fraud class actions, fueling investor uncertainty.

ICON’s audit committee is currently probing its accounting practices and internal controls. The company has said it plans to publish its delayed fourth-quarter and full-year 2025 results, along with its annual report, by April 30.

Headquartered in Dublin, Ireland, ICON is a top-tier global contract research organization (CRO) that conducts clinical trials and data analysis for pharmaceutical and biotech companies.

With growth slowing after major acquisitions and share buybacks—and regulatory risks on the rise—the market views the outcome of the accounting review and the timing of the postponed earnings release as a decisive moment for the stock’s performance and the restoration of investor trust.